跳至主要内容
临床试验/KCT0008513
KCT0008513尚未招募Unknown

Multi-center, Single-arm, Prospective cohort, Pilot study, Investigator initiated clinical performance study to evaluate treatment response of endocrine therapies with ovarian function suppression in premenopausal node-positive breast cancer patients with low genomic risk group using OncoFREE

Yonsei University Health System, Gangnam Severance Hospital0 个研究点目标入组 604 人开始时间: 待定最近更新:
适应症

试验速览

阶段
Unknown
状态
尚未招募
发起方
入组人数
604

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
35(Year) 至 50(Year)(—)
性别
All

入选标准

  • 1) Women between the ages of 35 and 50
  • 2) Patients who satisfy one of the following conditions
  • ? Pre-menopausal female, within 6 months of the last menstrual period
  • ? Patients who have undergone hysterectomy or whose menopausal status is unclear, with a serum FSH level of less than 30mIU/mL
  • 3) Patients diagnosed with breast cancer histopathologically and underwent surgery for curative purposes who have not yet started adjuvant chemotherapy or hormone therapy
  • 4) Patients with negative resection margins who have undergone breast conserving surgery, planned radiation therapy, or have undergone total mastectomy
  • 5) Patients with estrogen or progesterone receptor positive (=1%) on immunohistochemistry (IHC)
  • 6) Patients who are HER2 negative (IHC 0, 1+; if 2+, FISH or SISH negative) according to ASCO/CAP guidelines
  • 7) Patients with T-stage 1 or 2 after breast cancer surgery
  • 8) Patients with pathological lymph node stage pN1 (pN1mi, pN1a, pN1b, pN1c) after sentinel lymph node biopsy or axillary lymph node clearing
  • 9) Patients who have not performed other multigene tests (OncotypeDX, Mammaprint, Prosigna, EndoPredict, etc.) prior to study enrollment for breast cancer
  • 10) Patients who can obtain tissues necessary for OncoFREE® examination (10 FFPE 10 µm slides: Unstained_10µm X 9, H&E_4µm X 1)
  • 11) Patients with no clinically confirmed systemic metastases
  • 12) Patients whose general performance status is 0-2 points based on ECOG (European Cooperative Oncology Group). Patients without mental, physical, or geographical problems for appropriate periodic follow-up.
  • 13) Patients who signed the consent form before the start of the clinical trial Patients who signed the consent form before the start of the clinical trial

排除标准

  • 1) Patients with a history of cancer diagnosis within 5 years: Excluding skin cancer and cervical cancer in situ (thyroid cancer is possible, but undifferentiated thyroid cancer is not possible)
  • 2) age < 35
  • 3) Patients who received prior chemotherapy or prior hormone therapy for breast cancer
  • 4) Patients with inflammatory breast cancer, neuroendocrine tumor, or malignant phyllodes tumor
  • 5) Patients with bilateral breast cancer
  • 6) Patients who are deemed to require long-term systemic steroid therapy or immunosuppressive therapy
  • 7) Patients who have previously undergone bilateral salpingo-oophorectomy
  • 8) Patients who have previously received prophylactic tamoxifen or raloxifene
  • 9) Patients who have previously received radiation therapy to the breast
  • 10) Patients who are pregnant or lactating
  • 11) Among subjects of childbearing potential, those who do not agree to contraception* in a medically accepted method during this clinical trial
  • * Medically accepted methods of contraception: condoms, oral contraception continued for at least 3 months, use of injectable or implantable contraceptives, installation of intrauterine contraceptives, etc.
  • 12) Those who have difficulty understanding the contents of the questionnaire and completing the questionnaire

研究者

发起方
Yonsei University Health System, Gangnam Severance Hospital

相似试验